New Treatments for Rhabdomyosarcoma: the Importance of Target Practice.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 22629111.
- Also identified by PMC identifier 3271127.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To address the poor outcomes in rhabdomyosarcoma, particularly the alveolar subtype, new therapies are needed. Potential cancer-specific alterations that may be molecular targets include gene fusions or copy number changes. Following the latter strategy, an attractive antigene approach was developed to inhibit MYCN oncogene expression in rhabdomyosarcoma.